Sign Out
There are no adequate or well controlled studies in pregnant women. Following intranasal administration of the maximal recommended clinical dose, Mometasone plasma concentrations are not measurable; thus foetal exposure is expected to be negligible and the potential for reproductive toxicity very low.
As with other nasal corticosteroid preparations, Monitazone Nasal spray should not be used in pregnancy or lactation unless the potential benefit to the mother justifies any potential risk to the mother, foetus or infant. Infants born of mothers who received corticosteroids during pregnancy should be observed carefully for hypoadrenalism.
